Considering the Phase II and III trials together, on average, addition of SGLT inhibitors to insulin replacement in type 1 diabetes resulted in a 5–6 mmol/mol (0.4–0.5%) reduction in HbA1c, a 3–4 kg weight loss and a 10–15% reduction in total daily insulin dose. Here, INS is linked to type 1 diabetes mellitus.